OZEMPIC® 0.5mg

Description

OZEMPIC® 0.5mg is a once-weekly injectable GLP-1 receptor agonist indicated to improve glycemic control in adults with type 2 diabetes mellitus and reduce the risk of major cardiovascular events in patients with established cardiovascular disease. It contains semaglutide, a human GLP-1 analogue that enhances insulin secretion and suppresses glucagon in a glucose-dependent manner. The 0.5mg dose is the first therapeutic dose following initiation at 0.25mg, forming a key part of the titration strategy to improve glycemic control with reduced gastrointestinal side effects. It helps lower HbA1c levels and supports weight loss as part of comprehensive diabetes management.

GLP-1 analogue: Enhances insulin release and reduces glucagon levels only when glucose is elevated.
Once-weekly dosing: Administered subcutaneously, independent of meals.
Cardiovascular benefit: Shown to reduce CV risk in patients with type 2 diabetes and established cardiovascular disease